DISEASE CHARACTERISTICS:

• Histologically confirmed fallopian tube, ovarian epithelial, or primary peritoneal carcinoma

  • Stage II-IV disease

  • The following epithelial cell types are allowed:

    • Carcinosarcoma
    • Serous adenocarcinoma
    • Endometrioid adenocarcinoma
    • Mucinous adenocarcinoma
    • Undifferentiated carcinoma
    • Clear cell adenocarcinoma
    • Mixed epithelial carcinoma
    • Transitional cell carcinoma
    • Malignant Brenner's tumor
    • Adenocarcinoma not otherwise specified

• Must have undergone prior surgery for ovarian or peritoneal carcinoma within the past 12 weeks

  • Optimal (≤ 1 cm residual disease) or suboptimal residual disease following initial surgery
  • Must have a procedure for determining diagnosis of ovarian/peritoneal carcinoma with appropriate tissue for histologic evaluation

• Synchronous primary endometrial cancer or prior endometrial cancer allowed provided the following criteria are met:

  • Stage ≤ IB
  • Less than 3 mm invasion without vascular or lymphatic invasion
  • No poorly differentiated subtypes (e.g., grade 3, clear cell, or papillary serous)
• No epithelial ovarian carcinoma of low malignant potential (borderline carcinomas)
• No CNS disease (e.g., seizures not controlled with standard medical therapy) or metastasis

PATIENT CHARACTERISTICS:

• GOG performance status 0-2
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• INR ≤ 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thrombo-embolus) (applies to part C only)
• PTT < 1.2 times the upper limit of normal (applies to part C only)
• SGOT ≤ 2.5 times normal
• Alkaline phosphatase ≤ 2.5 times normal
• Bilirubin ≤ 1.5 times normal
• Creatinine ≤ 1.5 times normal
• No active bleeding
• Abnormal cardiac conduction (e.g., bundle branch block or heart block) allowed provided disease has remained stable for the past 6 months
• No unstable angina or myocardial infarction within the past 6 months
• No neuropathy (sensory and motor) > CTCAE grade 1
• Not pregnant or nursing
• Fertile patients must use effective contraception during and for at least 6 months after completion of study therapy
• No septicemia, severe infection, or acute hepatitis
• No other invasive malignancy within the past 5 years except non-melanoma skin cancer or localized breast cancer
• No circumstance that would preclude study participation
• No history of allergic reaction to polysorbate 80 (e.g., etoposide or vitamin E)
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies (applies to part C only)

• No clinically significant proteinuria

  • Must have urine protein-creatinine ratio (UPCR) < 1
• No serious, non-healing wound, ulcer, or bone fracture (applies to part C only)
• At least 3-6 months since prior abdominal fistula or gastrointestinal perforation and fully recovered (part C only)
• No history of intra-abdominal abscess within the past 28 days (applies to part C only)
• No active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels (applies to part C only)
• No history or evidence (upon physical examination) of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, or brain metastases (applies to part C only)
• No history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study (applies to part C only)
• No significant traumatic injury within 28 days (applies to part C only)

• No clinically significant cardiovascular disease, including any of the following (applies to part C only):

  • Uncontrolled hypertension, defined as systolic BP > 150 mm Hg or diastolic BP > 90 mm Hg
  • Myocardial infarction or unstable angina < 6 months prior to registration
  • New York Heart Association (NYHA) Grade II or greater congestive heart failure
  • Serious cardiac arrhythmia requiring medication
  • CTCAE Grade 2 or greater peripheral vascular disease (at least brief (< 24 hrs) episodes of ischemia managed non-surgically and without permanent deficit)
  • History of CVA within the past six months
• No clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration and/or nutrition (applies to part C only)

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior chemotherapy

  • Prior adjuvant chemotherapy for localized breast cancer allowed provided the therapy was completed at least 3 years before registration to study and the patient remains free of recurrent or metastatic disease
• No prior radiotherapy
• No prior cancer therapy that would contraindicate study treatment

• No anticipation of invasive procedures, including any of the following (applies to part C only):

  • Major surgical procedure or open biopsy within 28 days prior to the first date of bevacizumab therapy (cycle 2)
  • Major surgical procedure anticipated during the course of the study
  • Core biopsy within 7 days prior to the first date of bevacizumab therapy
• No prior therapy with any anti-VEGF drug, including bevacizumab (applies to part C only)